Serum lipids profiling perturbances in patients with ischemic heart disease and ischemic cardiomyopathy

[1] Ibanez B(2015)Evolving therapies for myocardial ischemia/reperfusion injury J Am Coll Cardiol 65 1454-1471

[2] Heusch G(2006)Contemporary definitions and classification of the cardiomyopathies: an american heart association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention Circulation 113 1807-1816

[3] Ovize M(2008)Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases Eur Heart J 29 270-276

[4] Van de Werf F(2018)Functional metabolomics characterizes a key role for N-acetylneuraminic acid in coronary artery diseases Circulation 137 1374-1390

[5] Maron BJ(2018)Integrating genes affecting coronary artery disease in functional networks by multi-OMICs approach Front Cardiovasc Med 5 89-1120

[6] Towbin JA(2012)Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function Circulation 126 1110-2017

[7] Thiene G(2018)MS-based lipidomics of human blood plasma: a community-initiated position paper to develop accepted guidelines J Lipid Res 59 2001-724

[8] Antzelevitch C(2018)Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial Eur J Heart Fail 20 1290-2181

[9] Corrado D(2013)Cardiac metabolism in heart failure: implications beyond ATP production Circ Res 113 709-3782

[10] Arnett D(2002)Dysfunction of mitochondrial respiratory chain complex I in human failing myocardium is not due to disturbed mitochondrial gene expression J Am Coll Cardiol 40 2174-e155

[1] Ibanez B(2015)Evolving therapies for myocardial ischemia/reperfusion injury J Am Coll Cardiol 65 1454-1471

[2] Heusch G(2006)Contemporary definitions and classification of the cardiomyopathies: an american heart association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention Circulation 113 1807-1816

[3] Ovize M(2008)Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases Eur Heart J 29 270-276

[4] Van de Werf F(2018)Functional metabolomics characterizes a key role for N-acetylneuraminic acid in coronary artery diseases Circulation 137 1374-1390

[5] Maron BJ(2018)Integrating genes affecting coronary artery disease in functional networks by multi-OMICs approach Front Cardiovasc Med 5 89-1120

[6] Towbin JA(2012)Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function Circulation 126 1110-2017

[7] Thiene G(2018)MS-based lipidomics of human blood plasma: a community-initiated position paper to develop accepted guidelines J Lipid Res 59 2001-724

[8] Antzelevitch C(2018)Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial Eur J Heart Fail 20 1290-2181

[9] Corrado D(2013)Cardiac metabolism in heart failure: implications beyond ATP production Circ Res 113 709-3782

[10] Arnett D(2002)Dysfunction of mitochondrial respiratory chain complex I in human failing myocardium is not due to disturbed mitochondrial gene expression J Am Coll Cardiol 40 2174-e155